Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share in 2Q25, improving on the original estimate of $1.22 per share, indicating effective cost management and operational efficiency. The positive clinical results for OKI-219, which was well-tolerated with no instances of hyperglycemia and only Grade 1 treatment-related adverse events, underscore the potential for successful therapeutic development in an underserved market. This combination of improved financial performance and promising clinical data supports a positive outlook for the company’s future growth prospects.

Bears say

OnKure Therapeutics Inc. is projected to incur a net loss of $4.56 per share for the full year 2025, a slight improvement from the previous estimate of $4.75 per share. The company faces significant risks, including the potential for negative clinical results from its lead asset, OKI-219, and possible delays in advancing its pipeline candidates. Additionally, there are concerns regarding regulatory approval timelines and intense competition, particularly from other mutant-selective PI3Kα inhibitors, which could undermine the company’s market position and future financial performance.

OKUR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Strong Buy based on their latest research and market trends.

According to 3 analysts, OKUR has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.